
Clinical trial reports on three incretin-related peptides

21 October 2026

Indexed clinical papers on semaglutide, tirzepatide, and retatrutide reported assigned-arm differences in percent body-weight change and recorded adverse events. Each note names the study type and a limitation. No use guidance is included.



Semaglutide

Study type: clinical. Wilding and colleagues (2021) reported a randomized, double-blind, placebo-controlled trial in adults with overweight or obesity and without diabetes. At 68 weeks, the paper reported a larger mean percent reduction in body weight in the semaglutide arm than in the placebo arm, and gastrointestinal events were recorded more often in the active arm. Limitation: one selected population and a fixed follow-up window; the report does not establish results outside that design.

Tirzepatide

Study type: clinical. Jastreboff and colleagues (2022) reported a phase 3 randomized trial in adults with obesity, or overweight plus a weight-related condition, and without diabetes. The paper reported larger mean percent body-weight changes in assigned tirzepatide arms than with placebo at 72 weeks, with gastrointestinal events among the events recorded. Limitation: eligibility criteria and trial duration restrict how far the measured differences can be read.

Retatrutide

All information and products discussed are for laboratory and research use only. Not for human or veterinary use. Not intended to diagnose, treat, cure, or prevent any disease.

Study type: clinical. Jastreboff and colleagues (2023) reported a phase 2 randomized trial. The paper reported percent body-weight change at 48 weeks that differed across assigned retatrutide arms and placebo, and it recorded gastrointestinal events. Limitation: phase 2 size and duration; the paper is not a completed later-phase dataset.

Sources

• Once-Weekly Semaglutide in Adults with Overweight or Obesity. 2021. https://doi.org/10.1056/NEJMoa2032183
• Tirzepatide Once Weekly for the Treatment of Obesity. 2022. https://doi.org/10.1056/NEJMoa2206038
• Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. 2023. https://doi.org/10.1056/NEJMoa2301972

All information and products discussed are for laboratory and research use only. Not for human or veterinary use. Not intended to diagnose, treat, cure, or prevent any disease.